The DWEYS peptide in systemic lupus erythematosus

Trends in Molecular Medicine

Volumn 18, Issue 4, 2012, Pages 215-223

  Bosch, Xavier ^a   Ramos Casals, Manuel ^a   Khamashta, Munther A ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Anti dsDNA antibodies; Blood brain barrier; DWEYS peptide; NMDA; NMDA receptors; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; ABETIMUS; AMG 557; ASPARTYLTRYPTOPHANYLGLUTAMYLTYROSYLSERINE; ATACICEPT; AZATHIOPRINE; BELIMUMAB; BG 9588; ECULIZUMAB; EDRATIDE; EPRATUZUMAB; FORIGERIMOD; GLUTATHIONE; IMMUNOMODULATING AGENT; INFLIXIMAB; LAQUINIMOD; MEMANTINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY INTERLEUKIN 10; MONOCLONAL ANTIBODY INTERLEUKIN 18; NOX E36; OCRELIZUMAB; PEPTIDE DERIVATIVE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; RONTALIZUMAB; SBI 087; SIFALIMUMAB; SPIEGELMER; TOCILIZUMAB; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ANTIBODY TITER; BLOOD BRAIN BARRIER; BRAIN FUNCTION; CROSS REACTION; DISEASE ACTIVITY; DRUG MECHANISM; DRUG WITHDRAWAL; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM;

ANIMALS; BLOOD-BRAIN BARRIER; DNA; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; N-METHYLASPARTATE; PEPTIDES; RECEPTORS, N-METHYL-D-ASPARTATE;

ANIMALIA;

EID: 84859428153     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.01.008     Document Type: Review

References (67)

1. D'Cruz D.P., et al. Systemic lupus erythematosus. Lancet 2007, 369:587-596.
2. Mitka M. Treatment for lupus, first in 50 years, offers modest benefits, hope to patients. JAMA 2011, 305:1754-1755.
3. Ramos-Casals M. et al. (2012) B-cell depleting therapy in systemic lupus erythematosus. Am. J. Med. (in press). doi:10.1016/j.amjmed.2011.09.010.
4. Hahn B.H., Tsao B.P. Antibodies to DNA. Dubois' Lupus Erythematosus 2002, 425-445. Lippincott, Williams & Wilkins. D.J. (Wallace, B.H. Hahn (Eds.).
5. Satoh M., et al. Clinical implication of autoantibodies in patients with systemic rheumatic diseases. Expert Rev. Clin. Immunol. 2007, 3:721-738.
6. Ehrenstein M.R., et al. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int. 1995, 48:705-711.
7. Tsao B., et al. Failed self-tolerance and autoimmunity in IgG anti-DNA transgenic mice. J. Immunol. 1992, 149:350-358.
8. Fenton K., et al. Anti-dsDNA antibodies promote initiation, and acquired loss of renal Dnase1 promotes progression of lupus nephritis in autoimmune (NZBxNZW) F1 mice. PLoS ONE 2009, 4:e8474.
9. Yung S., et al. Anti-DNA antibodies in the pathogenesis of lupus nephritis-the emerging mechanisms. Autoimmun. Rev. 2008, 7:317-321.
10. Avalos A.M., et al. Regulation of autoreactive B cell responses to endogenous TLR ligands. Autoimmunity 2010, 43:76-83.
11. Clynes R., et al. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998, 279:1052-1054.
12. Park S.Y., et al. Resistance of Fc receptor- deficient mice to fatal glomerulonephritis. J. Clin. Invest. 1998, 102:1229-1238.
13. ter Borg E.J., et al. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum. 1990, 33:634-643.
14. Katz J.B., et al. Mutational analysis of an autoantibody: differential binding and pathogenicity. J. Exp. Med. 1994, 180:925-932.
15. Rönnblom L. Potential role of IFN alpha in adult lupus. Arthritis Res. Ther. 2010, 12(Suppl 1):S3.
16. Gaynor B., et al. Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:1955-1960.
17. Diamond B., et al. Moving towards a cure: blocking pathogenic antibodies in systemic lupus erythematosus. J. Intern. Med. 2011, 269:36-44.
18. Diamond B. Antibodies and the brain: lessons from lupus. J. Immunol. 2010, 185:2637-2640.
19. Aranow C., et al. Glutamate receptor biology and its clinical significance in neuropsychiatric systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 2010, 36:187-201.
20. Kutsuwada T., et al. Molecular diversity of the NMDA receptor channel. Nature 1992, 358:36-41.
21. Collingridge G.L., et al. Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat hippocampus. J. Physiol. 1983, 334:33-46.
22. Huntley G.W., et al. Cellular and synaptic localization of NMDA and non-NMDA receptor subunits in neocortex: organizational features related to cortical circuitry, function and disease. Trends Neurosci. 1994, 17:536-543.
23. Ozawa S., et al. Glutamate receptors in the mammalian central nervous system. Prog. Neurobiol. 1998, 54:581-618.
24. DeGiorgio L.A., et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 2001, 7:1189-1193.
25. Cohen-Solal J., Diamond B. Lessons from an anti-DNA autoantibody. Mol. Immunol. 2011, 48:1328-1331.
26. Kowal C., et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:19854-19859.
27. The American College of Rheumatology Nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999, 42:599-608.
28. Garcia-Cavazos R., Brey R. Neuropsychiatric systemic lupus erythematosus. Systemic Lupus Erythematosus 2004, 757-784. Elsevier. 4th edn. R.G. Lahita (Ed.).
29. Kozora E., et al. Cognitive dysfunction in systemic lupus erythematosus: past, present, and future. Arthritis Rheum. 2008, 58:3286-3298.
30. LeDoux J.E. Emotion circuits in the brain. Annu. Rev. Neurosci. 2000, 23:155-184.
31. Diamond B., et al. Losing your nerves? Maybe it's the antibodies. Nat. Rev. Immunol. 2009, 9:449-456.
32. Kowal C., et al. Cognition and immunity; antibody impairs memory. Immunity 2004, 21:179-188.
33. Huerta P.T., et al. Immunity and behavior: antibodies alter emotion. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:678-683.
34. Sharma A., et al. Studies of human polyclonal and monoclonal antibodies binding to lupus autoantigens and cross-reactive antigens. Rheumatology (Oxford) 2003, 42:453-463.
35. Hanly J.G., et al. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J. Rheumatol. 2006, 33:1553-1558.
36. Steup-Beekman G., et al. Anti-NMDA receptor autoantibodies in patients with systemic lupus erythematosus and their first-degree relatives. Lupus 2007, 16:329-334.
37. Arinuma Y., et al. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2008, 58:1130-1135.
38. Fragoso-Loyo H., et al. Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PLoS ONE 2008, 3:e3347.
39. Yoshio T., et al. Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2006, 54:675-678.
40. Lahita R.G. Systemic lupus erythematosus: learning disability in the male offspring of female patients and relationship to laterality. Psychoneuroendocrinology 1988, 13:385-396.
41. Ross G., et al. Effects of mothers' autoimmune disease during pregnancy on learning disabilities and hand preference in their children. Arch. Pediatr. Adolesc. Med. 2003, 157:397-402.
42. Tincani A., et al. Impact of in utero environment on the offspring of lupus patients. Lupus 2006, 15:801-807.
43. Lee J.Y., et al. Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus. Nat. Med. 2009, 15:91-96.
44. Tchorbanov A.I., et al. Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice. Eur. J. Immunol. 2007, 37:3587-3596.
45. Voynova E., et al. An antibody-based construct carrying DNA-mimotope and targeting CR1 (CD35) selectively suppresses human autoreactive B-lymphocytes. Immunol. Lett. 2008, 116:168-173.
46. Mihaylova N., et al. An antibody-based construct carrying DNA-mimotope and targeting CR1 (CD35) selectively suppresses human autoreactive B-lymphocytes. Mol. Immunol. 2009, 47:123-130.
47. Bloom O., et al. Generation of a unique small molecule peptidomimetic that neutralizes lupus autoantibody activity. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:10255-10259.
48. Zang W., Murphy B. Peptide-mediated immunosuppression. Am. J. Ther. 2005, 12:592-599.
49. Burster T., Boehm B.O. Processing and presentation of (pro)-insulin in the MHC class II pathway: the generation of antigen-based immunomodulators in the context of type 1 diabetes mellitus. Diabetes Metab. Res. Rev. 2010, 26:227-238.
50. Czaja A.J. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr. Pharm. Des. 2011, 17:3120-3140.
51. Di Bisceglie M.B., et al. Pemphigus: the promises of peptide immunotherapy. Immunopharmacol. Immunotoxicol. 2009, 31:509-515.
52. Sakurai Y., et al. Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice. Arthritis Res. Ther. 2006, 8:R150.
53. Myers L.K., et al. Peptide-induced suppression of collagen-induced arthritis in HLA-DR1 transgenic mice. Arthritis Rheum. 2002, 46:3369-3377.
54. Wegner N., et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol. Rev. 2010, 233:34-54.
55. Naveh S., et al. Developing potent backbone cyclic peptides bearing the shared epitope sequence as rheumatoid arthritis drug-leads. Bioorg. Med. Chem. Lett. 2012, 22:493-496.
56. Bruner B.F., et al. Epitope specificity of myeloperoxidase antibodies: identification of candidate human immunodominant epitopes. Clin. Exp. Immunol. 2011, 164:330-336.
57. Amarilyo G., et al. Preclinical studies with synthetic peptides in systemic lupus erythematosus. Front. Biosci. 2012, 17:1940-1947.
58. Dieker J.W., et al. Mimotopes for lupus-derived anti-DNA and nucleosome-specific autoantibodies selected from random peptide phage display libraries: facts and follies. J. Immunol. Methods 2005, 296:83-93.
59. Kang H.K., et al. The histone peptide H4 71-94 alone is more effective than a cocktail of peptide epitopes in controlling lupus: immunoregulatory mechanisms. J. Clin. Immunol. 2011, 31:379-394.
60. Oka Y., et al. A single-stranded DNA-cross-reactive immunogenic epitope of human homocysteine-inducible endoplasmic reticulum protein. Scand. J. Immunol. 2011, 74:296-303.
61. Hirabayashi Y., et al. The endoplasmic reticulum stress-inducible protein, herp, is a potential triggering antigen for anti-DNA response. J. Immunol. 2010, 184:3276-3283.
62. Mahler M. Sm peptides in differentiation of autoimmune diseases. Adv. Clin. Chem. 2011, 54:109-128.
63. Telerman A., et al. Induction of hippocampal neurogenesis by a tolerogenic peptide that ameliorates lupus manifestations. J. Neuroimmunol. 2011, 232:151-157.
64. Muller S. Novel strategy in lupus therapy: from the peptide P140 to Lupuzor™. Ann. Pharm. Fr. 2011, 69:151-154.
65. Kumar S., et al. p185, an immunodominant epitope, is an autoantigen mimotope. J. Biol. Chem. 2011, 286:26220-26227.
66. Bertsias G.K., et al. Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann. Rheum. Dis. 2010, 69:1603-1611.
67. Yildirim-Toruner C., Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J. Allergy Clin. Immunol. 2011, 127:303-312.